Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus [13]

Acta Dermato-Venereologica

Volumn 81, Issue 3, 2001, Pages 223-

  Manjon Haces J A ^a   Vazquez Lopez F ^a   Gomez Diez S ^a   Hidalgo Garcia Y ^a   Perez Alvarez R ^a   Soler Sanchez T ^a   Perez Oliva N ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; CORTISONE; RIBAVIRIN;

DRUG INDUCED DISEASE; ECZEMA; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LICHENOID ERUPTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURIGO; SEBORRHEIC DERMATITIS; SKIN TOXICITY; TREATMENT OUTCOME; VIRUS HEPATITIS;

ADULT; ANTIVIRAL AGENTS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 17944373513     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155501750376447     Document Type: Letter

References (5)

1. Current therapy for chronic hepatitis C
2. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C: Relapsed and treatment-naive patients
3. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
4. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
5. High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus